NEW YORK (360Dx) – Paris-based Sebia said today that it has inked an agreement with Janssen Biotech to develop an in vitro diagnostic test that mitigates potential interference during immunofixation electrophoresis tests that measure a patient’s response to Darzalex (daratumumab), Janssen’s FDA-approved monoclonal antibody used to treat multiple myeloma.

Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.